Uric acid to albumin ratio as a novel predictor for coronary slow flow phenomenon in patients with chronic coronary syndrome and non-obstructive coronary arteries.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
13 Jul 2024
Historique:
received: 10 04 2024
accepted: 10 07 2024
medline: 14 7 2024
pubmed: 14 7 2024
entrez: 13 7 2024
Statut: epublish

Résumé

The plasma uric acid to albumin ratio (UAR) is considered as a novel indicator for Inflammation. However, the association between UAR and coronary slow flow phenomenon (CSFP) remains unclear. A total of 1328 individuals with chronic coronary syndrome (CCS) receiving coronary angiography (CAG) and found no obvious obstructive stenosis (< 40%) were included in this study. 79 individuals developed CSFP and were divided into CSFP group. The 1:2 age-matched patients with normal coronary blood flow were allocated to the control group (n = 158). The clinical characteristics, laboratory parameters including uric acid, albumin ratio, UAR and the angiographic characteristics were compared between the two groups. Patients with CSFP had a higher level of uric acid (392.3 ± 85.3 vs. 273.8 ± 71.5, P < 0.001), UAR (10.7 ± 2.2 vs. 7.2 ± 1.9, P < 0.001), but a lower level of plasma albumin (36.9 ± 4.2 vs. 38.5 ± 3.6, P = 0.003). Moreover, UAR increased as the numbers of vessels involved in CSFP increased. The logistic regression analysis demonstrated that UAR was independent predictors for CSFP. The Receiver operating characteristic (ROC) curve analysis showed that when UAR was more than 7.9, the AUC was 0.883 (95% CI: 0.840-0.927, p < 0.001), with the sensitivity and specificity were 78.2% and 88.2% respectively. Combined uric acid with plasma albumin, UAR could serve as an independent predictor for CSFP.

Sections du résumé

BACKGROUND BACKGROUND
The plasma uric acid to albumin ratio (UAR) is considered as a novel indicator for Inflammation. However, the association between UAR and coronary slow flow phenomenon (CSFP) remains unclear.
METHODS METHODS
A total of 1328 individuals with chronic coronary syndrome (CCS) receiving coronary angiography (CAG) and found no obvious obstructive stenosis (< 40%) were included in this study. 79 individuals developed CSFP and were divided into CSFP group. The 1:2 age-matched patients with normal coronary blood flow were allocated to the control group (n = 158). The clinical characteristics, laboratory parameters including uric acid, albumin ratio, UAR and the angiographic characteristics were compared between the two groups.
RESULTS RESULTS
Patients with CSFP had a higher level of uric acid (392.3 ± 85.3 vs. 273.8 ± 71.5, P < 0.001), UAR (10.7 ± 2.2 vs. 7.2 ± 1.9, P < 0.001), but a lower level of plasma albumin (36.9 ± 4.2 vs. 38.5 ± 3.6, P = 0.003). Moreover, UAR increased as the numbers of vessels involved in CSFP increased. The logistic regression analysis demonstrated that UAR was independent predictors for CSFP. The Receiver operating characteristic (ROC) curve analysis showed that when UAR was more than 7.9, the AUC was 0.883 (95% CI: 0.840-0.927, p < 0.001), with the sensitivity and specificity were 78.2% and 88.2% respectively.
CONCLUSION CONCLUSIONS
Combined uric acid with plasma albumin, UAR could serve as an independent predictor for CSFP.

Identifiants

pubmed: 39003493
doi: 10.1186/s12872-024-04040-5
pii: 10.1186/s12872-024-04040-5
doi:

Substances chimiques

Uric Acid 268B43MJ25
Biomarkers 0
Serum Albumin, Human ZIF514RVZR
ALB protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

358

Informations de copyright

© 2024. The Author(s).

Références

Beltrame JF. Defining the coronary slow flow phenomenon. Circulation Journal: Official J Japanese Circulation Soc. 2012;76(4):818–20.
doi: 10.1253/circj.CJ-12-0205
Yang SB, Cui Y, Hou JJ, Zhang H, Pei XY, Wang Y. Assessment of the relationship between plasma fibrinogen-to-albumin ratio and slow coronary flow phenomenon in patients without obstructive coronary artery disease. BMC Cardiovasc Disord. 2023;23(1):540.
doi: 10.1186/s12872-023-03579-z pubmed: 37932710 pmcid: 10629091
Dai XT, Kong TZ, Zhang XJ, Luan B, Wang Y, Hou AJ. Relationship between increased systemic immune-inflammation index and coronary slow flow phenomenon. BMC Cardiovasc Disord. 2022;22(1):362.
doi: 10.1186/s12872-022-02798-0 pubmed: 35941535 pmcid: 9358856
Kopetz V, Kennedy J, Heresztyn T, Stafford I, Willoughby SR, Beltrame JF. Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients. Cardiology. 2012;121(3):197–203.
doi: 10.1159/000336948 pubmed: 22508423
Genc Tapar G, Elcik D, Dogan A, Altunel E, Inanc MT, Alcali B, Boylug S, Oguzhan A, Topsakal R, Ergin A, Kalay N. An investigation of the relationship between arterial aortic stiffness and coronary slow flow that was detected during coronary angiography. Echocardiography. 2020;37(4):528–35.
doi: 10.1111/echo.14643 pubmed: 32240540
Wang Y, Jia PY, Chen BJ, Chen Y, Yu H, Yu Y, Yang HM, Jia DL, Ma CY. Evaluation of plasma thrombomodulin in patients with coronary slow Flow. Cardiology. 2017;138(3):141–6.
doi: 10.1159/000460239 pubmed: 28651248
Russo E, Bertolotto M, Zanetti V, Picciotto D, Esposito P, Carbone F, Montecucco F, Pontremoli R, Garibotto G, Viazzi F, Verzola D. Role of uric acid in vascular remodeling: Cytoskeleton Changes and Migration in VSMCs. Int J Mol Sci. 2023;24(3):2960.
doi: 10.3390/ijms24032960 pubmed: 36769281 pmcid: 9917405
Aroor AR, Jia G, Habibi J, Sun Z, Ramirez-Perez FI, Brady B, Chen D, Martinez-Lemus LA, Manrique C, Nistala R, Whaley-Connell AT, Demarco VG, Meininger GA, Sowers JR. Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice. Metabolism. 2017;74:32–40.
doi: 10.1016/j.metabol.2017.06.006 pubmed: 28764846 pmcid: 5577816
Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, Lauretani F, Bandinelli S, Senin U, Ferrucci L. Uric acid and inflammatory markers. Eur Heart J. 2006;27(10):1174–81.
doi: 10.1093/eurheartj/ehi879 pubmed: 16611671
Maloberti A, Biolcati M, Ruzzenenti G, Giani V, Leidi F, Monticelli M, Algeri M, Scarpellini S, Nava S, Soriano F, Oreglia J, Sacco A, Morici N, Oliva F, Piani F, Borghi C, Giannattasio C. The role of Uric Acid in Acute and Chronic Coronary syndromes. J Clin Med. 2021;10(20):4750.
doi: 10.3390/jcm10204750 pubmed: 34682873 pmcid: 8540994
Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep. 2013;15(3):175–81.
doi: 10.1007/s11906-013-0344-5 pubmed: 23588856 pmcid: 3736857
Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131. https://doi.org/10.1038/s41392-022-00955-7 . PMID: 35459215; PMCID: PMC9033871.
doi: 10.1038/s41392-022-00955-7 pubmed: 35459215 pmcid: 9033871
Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41(6):1211–9.
doi: 10.1002/hep.20720 pubmed: 15915465
Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582(13):1783–7.
doi: 10.1016/j.febslet.2008.04.057 pubmed: 18474236
Kalkan S, Cagan Efe S, Karagöz A, Zeren G, Yılmaz MF, Şimşek B, Batgerel U, Özkalaycı F, Tanboğa İH, Oduncu V, Karabay CY, Kırma C. A New Predictor of Mortality in ST-Elevation myocardial infarction: the uric acid albumin ratio. Angiology. 2022;73(5):461–9.
doi: 10.1177/00033197211066362 pubmed: 34989646
Çakmak EÖ, Bayam E, Çelik M, Kahyaoğlu M, Eren K, Imanov E, Karagöz A, İzgi İA. Uric acid-to-albumin ratio: a novel marker for the extent of coronary artery disease in patients with Non-ST-Elevated myocardial infarction. Pulse (Basel). 2021;8(3–4):99–107.
pubmed: 34307206
Li S, Chen H, Zhou L, Cui H, Liang S, Li H. The uric acid to albumin ratio: a novel predictor of long-term cardiac mortality in patients with unstable angina pectoris after percutaneous coronary intervention. Scand J Clin Lab Invest. 2022;82(4):304–10.
doi: 10.1080/00365513.2022.2084698 pubmed: 35675042
Leone MC, Gori T, Fineschi M. The coronary slow flow phenomenon: a new cardiac Y syndrome? Clin Hemorheol Microcirc. 2008;39(1–4):185–90.
doi: 10.3233/CH-2008-1079 pubmed: 18503124
Mintz GS, Painter JA, Pichard AD, Kent KM, Satler LF, Popma JJ, Chuang YC, Bucher TA, Sokolowicz LE, Leon MB. Atherosclerosis in angiographically normal coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol. 1995;25(7):1479–85.
doi: 10.1016/0735-1097(95)00088-L pubmed: 7759694
Xing Y, Guo JT, Gai LY, Liu B, Luo DL. Association of Uric Acid and C-reactive protein with the severity of coronary artery Disease using SYNTAX score and clinical SYNTAX score. Heart Surg Forum. 2019;22(3):E247–52.
doi: 10.1532/hsf.2397 pubmed: 31237552
Lin GM, Li YH, Zheng NC, Lai CP, Lin CL, Wang JH, Jaiteh LE, Han CL. Serum uric acid as an independent predictor of mortality in high-risk patients with obstructive coronary artery disease: a prospective observational cohort study from the ET-CHD registry, 1997–2003. J Cardiol. 2013;61(2):122–7.
doi: 10.1016/j.jjcc.2012.09.004 pubmed: 23088935
Wang X, Hou Y, Wang X, Li Z, Wang X, Li H, Shang L, Zhou J, Zhang Y, Ren M, Zhang Y. Relationship between serum uric acid levels and different types of atrial fibrillation: an updated meta-analysis. Nutr Metab Cardiovasc Dis. 2021;31(10):2756–65.
doi: 10.1016/j.numecd.2021.05.034 pubmed: 34348878
Caglar IM, Ozde C, Biyik I, Caglar FN, Akturk IF, Ugurlucan M, Karakaya O. Association between soluble lectin-like oxidized low-density lipoprotein receptor 1 levels and coronary slow flow phenomenon. Arch Med Sci. 2016;12(1):31–7.
doi: 10.5114/aoms.2015.51412 pubmed: 26925116 pmcid: 4754361
González-Pacheco H, Amezcua-Guerra LM, Sandoval J, Martínez-Sánchez C, Ortiz-León XA, Peña-Cabral MA, Bojalil R. Prognostic implications of serum albumin levels in patients with Acute Coronary syndromes. Am J Cardiol. 2017;119(7):951–8.
doi: 10.1016/j.amjcard.2016.11.054 pubmed: 28160977
Chien SC, Chen CY, Leu HB, Su CH, Yin WH, Tseng WK, Wu YW, Lin TH, Chang KC, Wang JH, Wu CC, Yeh HI, Chen JW. Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease. Int J Cardiol. 2017;241:1–5.
doi: 10.1016/j.ijcard.2017.04.003 pubmed: 28413113
Arques S, Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. J Card Fail. 2011;17(6):451–8.
doi: 10.1016/j.cardfail.2011.02.010 pubmed: 21624732
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–54. https://doi.org/10.1056/NEJM199902113400607 . Erratum in: N Engl J Med;340(17):1376.
doi: 10.1056/NEJM199902113400607 pubmed: 9971870
Yalcinkaya D, Karacali K, Ilhan BC, Yarlioglues M. Relation between serum uric acid to albumin ratio and severity of chronic coronary artery disease. Angiology. 2024;75(4):386–93.
doi: 10.1177/00033197231161902 pubmed: 36912476
Selçuk M, Çınar T, Şaylık F, Akbulut T, Asal S, Çiçek V, Hayıroğlu Mİ, Tanboğa İH. Predictive value of uric acid/albumin ratio for the prediction of new-onset atrial fibrillation in patients with ST-Elevation myocardial infarction. Rev Invest Clin. 2022;74(3):156–64.
pubmed: 35797660
Çınar T, Şaylık F, Hayıroğlu Mİ, Asal S, Selçuk M, Çiçek V, Tanboğa İH. The Association of Serum Uric Acid/Albumin Ratio with No-Reflow in patients with ST Elevation myocardial infarction. Angiology. 2023;74(4):381–6.
doi: 10.1177/00033197221110700 pubmed: 35726733
Nurkoç SG, Karayiğit O. The Association between No-Reflow and serum uric Acid/Albumin ratio in patients with Acute Myocardial Infarction without ST Elevation. Angiology. 2024;75(1):72–8.
doi: 10.1177/00033197221139685 pubmed: 37339132

Auteurs

Xiao-Jiao Zhang (XJ)

Department of Cardiology, The People's Hospital of Liaoning Province, The People's Hospital of China Medical University, Shenyang, China.

Ai-Jie Hou (AJ)

Department of Cardiology, The People's Hospital of Liaoning Province, The People's Hospital of China Medical University, Shenyang, China.

Bo Luan (B)

Department of Cardiology, The People's Hospital of Liaoning Province, The People's Hospital of China Medical University, Shenyang, China.

Cheng-Fu Wang (CF)

Department of Cardiology, The People's Hospital of Liaoning Province, The People's Hospital of China Medical University, Shenyang, China.

Jia-Jin Li (JJ)

Department of Cardiology, The People's Hospital of Liaoning Province, The People's Hospital of China Medical University, Shenyang, China. drlijiajin@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH